• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence?].

作者信息

Soška Vladimír

出版信息

Vnitr Lek. 2021 Winter;67(1):37-40.

PMID:33752389
Abstract

Treatment of dyslipidemia and hypertension is a key step for reducing the risk of atherosclerotic cardiovascular disease. Dyslipidemia and hypertension often occur in one patient at the same time, so both of these risk factors need to be addressed at the same time. It is better to start therapy before the patient is at high risk of a fatal cardiovascular event. To improve the patients prognosis, it is important not only to achieve the target LDL-cholesterol value and the optimal blood pressure value, but it is also very important (and often more difficult) to maintain the patients good and long-term adherence to established combination pharmacotherapy. For better adherence to long-term therapy also contributes reduction the number of tablets, which can be achieved through the use of a fixed combination of statins and antihypertensive agents.

摘要

相似文献

1
[Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence?].
Vnitr Lek. 2021 Winter;67(1):37-40.
2
[News in the treatment of hypertension and dyslipidemia].[高血压和血脂异常的治疗进展]
Vnitr Lek. 2017 Summer;63(5):333-337.
3
[How to create cooperative patient for antihypertensive and hypolipidemic therapy].[如何创建用于抗高血压和降血脂治疗的合作患者]
Vnitr Lek. 2017 Spring;63(4):272-276.
4
Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.2型糖尿病患者心血管风险的管理作为心脏代谢综合征的一个组成部分。
J Cardiometab Syndr. 2006 Spring;1(2):133-40. doi: 10.1111/j.1559-4564.2006.05487.x.
5
The evening versus morning polypill utilization study: the TEMPUS rationale and design.晚间与晨间复方制剂使用研究:TEMPUS的基本原理与设计
Eur J Prev Cardiol. 2014 Apr;21(4):425-33. doi: 10.1177/2047487313476961. Epub 2013 Feb 4.
6
[Dyslipidemia and hypertension - what to worry about more?].
Vnitr Lek. 2018 Spring;64(4):395-401.
7
The role of statins in endothelial dysfunction in hypertension.他汀类药物在高血压患者内皮功能障碍中的作用。
Curr Opin Cardiol. 2006 Jul;21(4):316-21. doi: 10.1097/01.hco.0000231401.87232.71.
8
[Hypertension and dyslipidemia treament in stroke].[中风中的高血压和血脂异常治疗]
Vnitr Lek. 2022 Fall;68(3):172-177.
9
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.氨氯地平和阿托伐他汀固定复方制剂在心血管风险管理中的应用:患者视角
Vasc Health Risk Manag. 2009;5(1):377-87. doi: 10.2147/vhrm.s3339.
10
Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?预防加拿大人群的心血管疾病:高血压或血脂异常的治疗是否具有成本效益?
Can J Cardiol. 2008 Dec;24(12):891-8. doi: 10.1016/s0828-282x(08)70695-0.